References
1. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. Jama . May 19 2020;323(19):1945-1960.
2. Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol . Feb 2007;156(2):258-262.
3. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis.Lancet . Apr 3 2021;397(10281):1301-1315.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.J Am Acad Dermatol . Apr 2019;80(4):1029-1072.
5. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.J Am Acad Dermatol . Feb 2021;84(2):432-470.
6. Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol . Aug 2013;27(8):931-951.
7. Mason A, Mason J, Cork M, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review.J Am Acad Dermatol . Nov 2013;69(5):799-807.
8. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev . Mar 28 2013;(3):Cd005028.
9. Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol . Mar 2017;176(3):604-614.
10. Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol . May 2013;168(5):954-967.
11. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.Ann Intern Med . Jun 2 2015;162(11):777-784.
12. Kelley GA, Kelley KS. Statistical models for meta-analysis: A brief tutorial. World J Methodol . Aug 26 2012;2(4):27-32.
13. Thom H, White IR, Welton NJ, Lu G. Automated methods to test connectedness and quantify indirectness of evidence in network meta-analysis. Res Synth Methods . Mar 2019;10(1):113-124.
14. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med . Mar 30 2010;29(7-8):932-944.
15. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods . Jun 2012;3(2):98-110.
16. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One . 2013;8(10):e76654.
17. Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses.Syst Rev . Apr 12 2017;6(1):79.
18. Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol . Oct 3 2016;16(1):15.
19. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med . Dec 9 2021;385(24):2219-2229.
20. Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol . Mar 2019;80(3):714-721.
21. Cai L, Chen GH, Lu QJ, et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl) . Nov 9 2020;133(24):2905-2909.
22. Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial.J Eur Acad Dermatol Venereol . Dec 2012;26(12):1516-1521.
23. Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med . Jul 16 2020;383(3):229-239.
24. Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol . Feb 2022;36(2):228-236.
25. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris–A randomized phase II study. J Dermatolog Treat . 2016;27(2):120-127.
26. Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris–a Randomized Phase III Study (PSO-FAST).J Drugs Dermatol . Dec 2015;14(12):1468-1477.
27. Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol . Jan 2017;31(1):119-126.
28. Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol . Aug 2018;79(2):287-293.
29. Lebwohl M, Kircik LH, Moore A, Gold LS, Del Rosso J, Draelos ZD, et al. Once-daily roflumilast cream 0.3%, a potent phosphodiesterase-4 inhibitor, provided safe and effective treatment of psoriasis in the DERMIS-1 and DERMIS-2 phase 3 trials [abstract 2063]. EADV 30th Congress; 2021.
30. Langley RG, Gupta A, Papp K, Wexler D, Østerdal ML, Curčić D. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology .
31. Sugarman JL, Gold LS, Lebwohl MG, Pariser DM, Alexander BJ, Pillai R. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. J Drugs Dermatol . Mar 1 2017;16(3):197-204.
32. Lebwohl M, Tyring S, Bukhalo M, et al. Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. J Clin Aesthet Dermatol . Feb 2016;9(2):34-41.
33. Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol . Jan 2013;12(1):92-98.
34. Feldman SR, Matheson R, Bruce S, et al. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol . Aug 1 2012;13(4):261-271.
35. Green LJ, Kerdel FA, Cook-Bolden FE, et al. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials. J Drugs Dermatol . Oct 1 2018;17(10):1062-1069.
36. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.Bmj . Oct 18 2011;343:d5928.
37. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol . Jan 2019;80(1):27-40.
38. Puig L, Carrascosa JM, Belinchón I, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr . Jul-Aug 2013;104(6):488-496.
39. Stein Gold LF. Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence. Semin Cutan Med Surg . Mar 2016;35(2 Suppl 2):S36-44; quiz S45.
40. Kragballe K, van de Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol . May 2014;28 Suppl 2:10-21.
41. Lé AM, Torres T. New Topical Therapies for Psoriasis. Am J Clin Dermatol . Jan 2022;23(1):13-24.
42. Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol . 2015;172(5):1395-1406.
43. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol . Jul 2013;169(1):137-145.
44. Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: A review of applications in dermatology. J Am Acad Dermatol . Sep 2018;79(3):535-544.
45. Nogueira M, Puig L, Torres T. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs . Mar 2020;80(4):341-352.
46. Takahashi H, Katayama H, Uwajima Y, et al. Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence. J Dermatol . Nov 2020;47(11):1249-1256.